Table 3. Primary outcome measures of GSH and all other variables.

	All patients	RRMS	PPMS	SPMS	Controls
Number of subjects	61	21	20	20	28
frontal GSH (μmol/g tissue)	1.08±0.17	1.16±0.12	1.04±0.20	1.05±0.16	1.23±0.11
parietal GSH (μmol/g tissue)	1.09±0.16	1.15±0.10	1.06±0.20	1.07±0.14	1.21±0.11
Fronto-parietal GSH (μmol/g tissue)	1.09±0.15	1.15±0.11	1.05±0.18	1.06±0.14	1.22±0.08
T2LV (ml) (median; range)	17.76±16.60; 12.61; 1.56-68.26	15.52±14.20; 12.61; 1.56-49.84	14.68±16.35; 8.22; 1.75-65.16	23.19±18.54; 16.01; 2.78-68.26	0.65±0.99; 0.35; 0.00-3.70
BPF	0.73±0.04	0.76±0.04	0.71±0.03	0.71±0.04	0.78±0.04
GMF	0.45±0.03	0.46±0.03	0.43±0.03	0.44±0.03	0.48±0.05
WMF	0.28±0.03	0.30±0.03	0.28±0.02	0.28±0.03	0.30±0.03

Note: All data are shown in mean ± SD. T2 hyper-intense lesion volumes (T2LV) are shown in mean ± SD as well as median and range due to its asymmetrical distribution. BPF: brain parenchymal fraction; GMF: gray matter fraction; WMF: white matter fraction. GSH concentrations in progressive MS (PPMS and SPMS) were lower than those of controls and RRMS, while no GSH difference was found between RRMS and controls, and between PPMS and SPMS. Similarly, BPF, GMF, and WMF in progressive MS were lower than those in controls and RRMS, while no difference was found between PPMS and SPMS. Additionally GMF in RRMS was lower than that in controls.